DK3254695T3 - Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer - Google Patents

Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer Download PDF

Info

Publication number
DK3254695T3
DK3254695T3 DK17171169.0T DK17171169T DK3254695T3 DK 3254695 T3 DK3254695 T3 DK 3254695T3 DK 17171169 T DK17171169 T DK 17171169T DK 3254695 T3 DK3254695 T3 DK 3254695T3
Authority
DK
Denmark
Prior art keywords
claudin
antibodies
combination therapy
cancer treatment
therapy involving
Prior art date
Application number
DK17171169.0T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem Türeci
Rita Mitnacht-Kraus
Stefan Denis Jacobs
Magdalena Jadwiga Utsch
Cornelia Adriana Maria Heinz
Christiane Regina Stadler
Original Assignee
Astellas Pharma Inc
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3254695(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/002210 external-priority patent/WO2013174403A1/en
Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK3254695T3 publication Critical patent/DK3254695T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK17171169.0T 2012-05-23 2013-05-21 Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer DK3254695T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/002210 WO2013174403A1 (en) 2012-05-23 2012-05-23 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP13724523.9A EP2852408B1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
DK3254695T3 true DK3254695T3 (da) 2020-11-30

Family

ID=52544200

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17171169.0T DK3254695T3 (da) 2012-05-23 2013-05-21 Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer

Country Status (9)

Country Link
EP (6) EP3254695B1 (da)
CY (3) CY1119549T1 (da)
DK (1) DK3254695T3 (da)
HR (1) HRP20171218T1 (da)
ME (1) ME02932B (da)
PL (2) PL3254695T3 (da)
RS (1) RS56187B1 (da)
SI (1) SI2852408T1 (da)
SM (1) SMT201700387T1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3254695T3 (da) 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
EP3858384A4 (en) 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CA3141504A1 (en) 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
CN115073596B (zh) * 2021-03-10 2025-06-27 上海莱馥医疗科技有限公司 一种人源化Claudin18.2抗体及其应用
CN114685670B (zh) * 2020-12-31 2025-06-27 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP2011529172A (ja) * 2008-07-25 2011-12-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング モノクローナル抗体によるレセプター結合飽和を測定する方法
WO2011090005A1 (ja) * 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
DK3254695T3 (da) 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer

Also Published As

Publication number Publication date
CY1126654T1 (el) 2026-02-25
EP2852408B1 (en) 2017-05-17
EP4556071A3 (en) 2025-08-27
EP4556070A2 (en) 2025-05-21
SMT201700387T1 (it) 2017-09-07
SI2852408T1 (sl) 2017-10-30
EP3254695A1 (en) 2017-12-13
ME02932B (me) 2018-04-20
EP4556071A2 (en) 2025-05-21
EP4364756A2 (en) 2024-05-08
EP2852408A1 (en) 2015-04-01
EP4364756A3 (en) 2024-07-31
EP3254695B1 (en) 2020-09-09
PL2852408T3 (pl) 2017-12-29
HRP20171218T1 (hr) 2017-10-20
RS56187B1 (sr) 2017-11-30
EP3791896B1 (en) 2024-01-10
PL3254695T3 (pl) 2021-04-06
EP3791896A1 (en) 2021-03-17
CY1119549T1 (el) 2018-03-07
CY1123593T1 (el) 2022-03-24
EP4556070A3 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
DK2976360T3 (da) Terapi, hvori der er involveret antistoffer mod claudin 18.2, til behandling af cancer
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
DK2847225T3 (da) Antistoffer mod claudin 18.2, der kan anvendes til cancerdiagnose
DK2958945T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til behandling af cancer
DK3283521T5 (da) Lægemiddelkonjugater, der omfatter antistoffer mod claudin 18.2
PL2852408T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
DK3725810T3 (da) Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
BR112014028306A2 (pt) métodos para tratamento de câncer gástrico.